OCS OCULIS HOLDING AG

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

ZUG, Switzerland, March 14, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to annual equity incentive awards granted to members of the executive committee of the Company, as well as purchase of ordinary shares by a member of the Company´s Board of Direcors.

Attachments



EN
14/03/2025

Underlying

OCSOCULIS HOLDING AG

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OCULIS HOLDING AG

 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Announces Oversubscribed $110 Million Financing to Accelerate P...

Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development ZUG, Switzerland, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced the pricing of offerings of an aggregate of 5,432,098 of its ordinary shares, CHF 0.01 nominal value per share, at a price of $20.25 per share for total gross proceeds of $110 million before deducting under...

October 30, 2025 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Announces Oversubscribed $110 Million Financing to Accelerate P...

Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development ZUG, Switzerland, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced the pricing of offerings of an aggregate of 5,432,098 of its ordinary shares, CHF 0.01 nominal value per share, at a price of $20.25 per share for total gross proceeds of $110 million before deducting under...

October 30, 2025 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis greinir frá umframeftirspurn í 110 milljóna USD fjármögnun sem ...

Oculis greinir frá umframeftirspurn í 110 milljóna USD fjármögnun sem er ætlað til að hraða klínískri þróun Privosegtor ZUG, Sviss, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) („Oculis“ eða „félagið“), alþjóðlegt líftæknilyfjafyrirtæki með áherslu á á nýsköpun til að meðhöndla augnsjúkdóma og augntaugasjúkdóma og mæta verulegum óuppfylltum læknisfræðilegum þörfum, greinir í dag frá því að ákvörðun hafi verið tekin um verð og úthlutun almennra hluta í útboði þar sem seldir voru 5.432.098 almennir hlutir, hver að nafnverði 0,01 CHF, á verðinu 20,25 USD á hlu...

October 30, 2025 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Publishes Notifications of Transactions by Persons Discharging ...

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities ZUG, Switzerland, Oct. 14, 2025 (GLOBE NEWSWIRE) -- The attached two notifications relate to the exercise of vested stock options to purchase ordinary shares previously granted to a director of the Company, and the subsequent sale of those ordinary shares. These transactions were entered into pursuant to a 10b5-1 trading plan, in accordance with Rule 10b5-1(c)(1) of the Securities Exchange Act of 1934, as amended. Attachments ...

October 14, 2025 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator...

Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025 ZUG, Switzerland, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis’ innovative late-stage pipeline will be highlighted at Eyecelerator and at the American Academy of Ophthalmology (AAO) Annual Meeting. At Eyecelerator, Riad Sherif, MD, Oculis’ Chief Executive Officer, will provide an upd...

October 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch